RxDoctor Payments DataLook up a doctor →

Jared Brosch, MD

Neurology · Indianapolis, INNPI 1528383064

Payments from drug & device makers

$4,710,582in general payments, 2019–2025

Across 585 payments — averaging $8052.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2.7M
  • Eisai Inc.$1.1M
  • Alnylam Pharmaceuticals Inc.$597K
  • AbbVie$146K
  • Biogen$94K
  • Takeda Pharmaceuticals U.S.A., Inc.$38K
  • plus $83K from 5 others
$7,244in research payments, 2019–2025

Across 7 payments — averaging $1034.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K

What the payments were for

  • Consulting fees$43,31963%
  • Speaking & faculty fees$20,23830%
  • Travel & lodging$3,8346%
  • Food & beverage$1,0131%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,710,582 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$92,800
Medicare patients
465
Services billed
966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rivastigmine100$18,394
Emgality PenGalcanezumab-Gnlm20$13,996
XareltoRivaroxaban13$7,523
Memantine Hcl213$7,214
Donepezil Hcl608$5,977
Carbidopa-LevodopaCarbidopa/Levodopa197$4,302
Aripiprazole18$3,163
Levetiracetam93$2,827
Sertraline Hcl337$2,355
RivastigmineRivastigmine Tartrate12$2,087
Lacosamide36$2,008
Olanzapine69$1,793
Duloxetine Hcl99$1,315
Frovatriptan Succinate16$1,296
Trazodone Hcl200$1,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$31,171$1,79369 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Indiana.

Other neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →